89bio
Yahoo Finance • 7 months ago
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trad... Full story
Yahoo Finance • 10 months ago
11 Best Small-Cap Growth Stocks to Invest In
In this piece, we will take a look at the 11 best small-cap growth stocks to invest in. If you want to skip our primer about the benefits and drawbacks of investing in small cap stocks, then you can take a look at the 5 Best Small-Cap Grow... Full story
Yahoo Finance • last year
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests (NITs) of liver injury/inflammation and fibrosis in NASH patients with fibrosis... Full story
Yahoo Finance • last year
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
SAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabol... Full story
Yahoo Finance • last year
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic (F4) patients at week 24— —A responder analysis suggests that responses in... Full story
Yahoo Finance • last year
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
–Pegozafermin granted Breakthrough Therapy Designation (BTD) for the treatment ofnonalcoholic steatohepatitis (NASH) with fibrosis– –Feedback from regulatory agencies on pegozafermin Phase 3 development program in NASH expected this quart... Full story
Yahoo Finance • last year
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabo... Full story
Yahoo Finance • last year
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Oct. 03, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment... Full story
Yahoo Finance • last year
89bio to Participate in the 2023 Cantor Global Healthcare Conference
SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metab... Full story
Yahoo Finance • last year
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabo... Full story
Yahoo Finance • last year
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, July 12, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment... Full story
Yahoo Finance • 2 years ago
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and tolerability profile – – SHTG Phase 3 ENTRUST trial initiated in May 2023 – S... Full story
Yahoo Finance • 2 years ago
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints – – New data showed pegozafermin resulted in signi... Full story
Yahoo Finance • 2 years ago
89bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 02, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabol... Full story
Yahoo Finance • 2 years ago
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
SAN FRANCISCO, March 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and ca... Full story
Yahoo Finance • 2 years ago
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, March 22, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and ca... Full story
Yahoo Finance • 2 years ago
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) - - 30mg QW dose had a placebo-ad... Full story
Yahoo Finance • 2 years ago
12 Best Biotech Stocks To Buy Under $20
In this piece, we will take a look at the 12 best biotechnology stocks to buy under $20. For more stocks, head on over to 5 Best Biotech Stocks To Buy Under $20. The biotechnology industry is one of the hottest sectors right now, particul... Full story
Yahoo Finance • 2 years ago
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of two SHTG Phase 3 trials in the second... Full story
Yahoo Finance • 2 years ago
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status – SAN FRANCISCO, March 04,... Full story
